| タイトル |
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
|
| 著者 |
Sakurai Yuuichi
Takabayashi Nobuyoshi
Kudou Kentaro
Araki Takahiro
Miyagi Takuya
Iwakiri Katsuhiko
Ashida Kiyoshi
|
| 収録物名 |
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
|
| 巻 | 10 |
| 収録物識別子 |
ISSN 2155-384X
|
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
LIPPINCOTT WILLIAMS & WILKINS
|
| 発行日 | 2019-11 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.14309/ctg.0000000000000101
[PMID] 31770139
|
| 備考 | This study was sponsored by Takeda Pharmaceutical Company Limited, manufacturer/licensee of Takecab or Vocinti. Takeda Pharmaceutical Company Limited was involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Thao Le, MD, PhD, and Tania Dickson, PhD, CMPP, of ProScribe-Envision Pharma Group and was funded by Takeda Pharmaceutical Company Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3). Ethical approval and informed consent: The study was registered (ClinicalTrials.gov: NCT02954848), approved by the local institutional review board, and conducted at 44 study sites in Japan in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guideline for Good Clinical Practice, and applicable Japanese regulations. All patients signed the informed consent form before participation. |
